Panacea Index Logo

Command Palette

Search for a command to run...

Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis.

Nephrology (Carlton, Vic.)
March 1, 2010
Nuria Garcia-Fernandez et al. (5 authors)
Journal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov'tHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine if N-acetylcysteine could neutralize the oxidative and inflammatory effects of iron administration during haemodialysis.

Results Summary

N-acetylcysteine significantly reduced malondialdehyde levels (a marker of oxidative stress) when administered with a low iron dose (50 mg), but had no effect on other inflammatory or endothelial dysfunction markers. Haemodialysis itself increased oxidative stress and inflammation, while iron had minor effects on inflammation and oxidative stress.

Population

40 patients undergoing haemodialysis.

Effective Dosage

Not specified (infused before iron sucrose at 50 or 100 mg).

Duration

Not specified.

Interactions

None mentioned.

Extracted Claims (21)
InterventionDirectionEndpointPopulationDosageImpactClaim #
Haemodialysis
increase
plasma vWF
patients undergoing haemodialysis
P < 0.001
produced significant increase
#1
Haemodialysis
increase
sICAM-1
patients undergoing haemodialysis
P < 0.001
produced significant increase
#2
Haemodialysis
increase
malondialdehyde
patients undergoing haemodialysis
P < 0.001
produced significant increase
#3
Haemodialysis
increase
IL-8
patients undergoing haemodialysis
P < 0.001
produced significant increase
#4
Haemodialysis
increase
CD11b/CD18 expression in monocytes
patients undergoing haemodialysis
P < 0.001
produced significant increase
#5
Haemodialysis
decrease
total antioxidant capacity
patients undergoing haemodialysis
P < 0.001
decrease
#6
Iron
increase
plasma malondialdehyde
patients undergoing haemodialysis
-
induced significant increase
#7
Iron
increase
IL-8 in monocytes
patients undergoing haemodialysis
-
induced significant increase
#8
Iron
no change
total antioxidant capacity
patients undergoing haemodialysis
-
had no effect
#9
Iron
no change
CD11b/CD18 expression
patients undergoing haemodialysis
-
had no effect
#10
Iron
no change
plasma IL-8
patients undergoing haemodialysis
-
had no effect
#11
Iron
no change
vWF
patients undergoing haemodialysis
-
had no effect
#12
Iron
no change
sICAM-1
patients undergoing haemodialysis
-
had no effect
#13
N-acetylcysteine
decrease
malondialdehyde
patients undergoing haemodialysis
P = 0.040
produced a significant decrease
#14
Standard (100 mg) and low (50 mg) doses of iron during haemodialysis
no change
endothelium
patients undergoing haemodialysis
-
had no effects
#15
Iron
increase
inflammation
patients undergoing haemodialysis
-
only had minor effects
#16
Iron
increase
oxidative stress
patients undergoing haemodialysis
-
produced an increase
#17
N-acetylcysteine
decrease
oxidative stress
patients undergoing haemodialysis
-
neutralized
#18
Haemodialysis
increase
oxidative stress
patients undergoing haemodialysis
-
caused a significant increase
#19
Haemodialysis
increase
inflammation
patients undergoing haemodialysis
-
caused a significant increase
#20
Haemodialysis
increase
endothelial dysfunction markers
patients undergoing haemodialysis
-
caused a significant increase
#21
Abstract

AIM: Haemodialysis induces endothelial dysfunction by oxidation and inflammation. Intravenous iron administration during haemodialysis could worsen endothelial dysfunction. The aim of this study was to ascertain if iron produces endothelial dysfunction and the possible neutralizing effect of N-acetylcysteine when infused before iron. The oxidative and inflammatory effects of iron during haemodialysis were also assessed. METHODS: Forty patients undergoing haemodialysis were studied in a randomized and cross-over design with and without N-acetylcysteine infused before iron sucrose (50 or 100 mg). Plasma Von Willebrand factor (vWF), soluble intercellular adhesion molecule-1 (sICAM-1) levels, malondialdehyde, total antioxidant capacity, CD11b/CD18 expression in monocytes, interleukin (IL)-8 in monocytes and plasma IL-8 were studied at baseline and during haemodialysis. RESULTS: Haemodialysis produced significant (P < 0.001) increase in plasma vWF, sICAM-1, malondialdehyde, IL-8 and CD11b/CD18 expression in monocytes, as well as decrease in total antioxidant capacity. Iron induced significant increase in plasma malondialdehyde and IL-8 in monocytes, but had no effect on total antioxidant capacity, CD11b/CD18 expression, plasma IL-8, vWF and sICAM-1. The addition of N-acetylcysteine to 50 mg of iron produced a significant (P = 0.040) decrease in malondialdehyde. CONCLUSION: Standard (100 mg) and low (50 mg) doses of iron during haemodialysis had no effects on endothelium. Iron only had minor effects on inflammation and produced an increase in oxidative stress, which was neutralized by N-acetylcysteine at low iron dose. Haemodialysis caused a significant increase in oxidative stress, inflammation and endothelial dysfunction markers.

Medical Subject Headings (MeSH)
AcetylcysteineAgedAntioxidantsBiomarkersCD11b AntigenCD18 AntigensCross-Over StudiesEndothelium, VascularFemaleFerric CompoundsFerric Oxide, SaccharatedGlucaric AcidHematinicsHumansInflammationInflammation MediatorsInfusions, IntravenousIntercellular Adhesion Molecule-1Interleukin-8MaleMalondialdehydeMiddle AgedOxidative StressProspective StudiesRenal DialysisTime FactorsTreatment Outcomevon Willebrand Factor
Study Links
Quality Scores
SafetyNot Assessed
Efficacy70/10
Quality85/10
Citation Metrics
Total Citations29
Citations/Year1.9
Relative Citation Ratio0.90
NIH Percentile46.4%
Research Impact Scores
APT Score0.75
Weight Score1.33
Normalized Score0.65
Related Supplements